What is CUE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.20B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CUE?

P/E (TTM) is n/a and 52-week range is $4.97 to $45.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CUE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CUE?

The company profile lists revenue (TTM) near $24M, net income (TTM) near $-10.48B, EPS (TTM) near $-26.99 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cue Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 4M shares outstanding, ISIN US22978P2056 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cue Biopharma Inc

$CUE

Health Care · Biotechnology

IR Run Scenarios

$27.66

+23.87%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cue Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2018-01-02. Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Employees

Website

www.cuebiopharma.com/

IPO

2018-01-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)